Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study (Q40778187)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study (English)

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

9

object named as

Ronald S Go

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

author name string

Julie E Chang

1

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Thomas Havighurst

2

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

KyungMann Kim

3

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Jens Eickhoff

4

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Anne M Traynor

5

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Rachel Kirby-Slimp

6

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Lynn M Volk

7

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Jae Werndli

8

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Matthias Weiss

10

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Jules Blank

11

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Brad S Kahl

12

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

language of work or name

0 references

publication date

23 February 2016

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

British Journal of Haematology

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

173

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

2

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

283-291

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

22 June 2018

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

19 August 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

19 August 2018

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

19 August 2018

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5923897

19 August 2018

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13957

21 January 2018

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://pubmed.ncbi.nlm.nih.gov/26913697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/26913697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/BJH.13957

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 June 2018

http://europepmc.org/abstract/PMC/5923897

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40778187&oldid=1907000410"